Abstract
BackgroundTreatment standard for patients with atypical or anaplastic meningioma is neurosurgical resection. With this approach, local control ranges between 50% and 70%, depending on resection status. A series or smaller studies has shown that postoperative radiotherapy in this patient population can increase progression-free survival, which translates into increased overall survival. However, meningiomas are known to be radioresistant tumors, and radiation doses of 60 Gy or higher have been shown to be necessary for tumor control.Carbon ions offer physical and biological characteristics. Due to their inverted dose profile and the high local dose deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an increased relative biological effectiveness (RBE), which can be calculated between 2 and 5 depending on the cell line as well as the endpoint analyzed.First data obtained within the Phase I/II trial performed at GSI in Darmstadt on carbon ion radiotherapy for patients with high-risk meningiomas has shown safety, and treatment results are promising.Methods/designThe Phase II-MARCIE-Study will evaluate a carbon ion boost applied to the macroscopic tumor in conjunction with photon radiotherapy in patients with atypical menigiomas after incomplete resection or biopsy.Primary endpoint is progression-free survival, secondary endpoints are overall survival, safety and toxicity.DiscussionBased on published data on the treatment of atypical meningiomas with carbon ions at GSI, the present study will evaluate this treatment concept in a larger patient population and will compare outcome to current standard photon treatment.Trial registrationNCT01166321
Highlights
Treatment standard for patients with atypical or anaplastic meningioma is neurosurgical resection
5-10% of meningiomas are of non-benign histology and are associated with less favourable outcome; they are characterized by locally aggressive
Follow-up After completion of study treatment no further adjuvant treatment is scheduled or recommended
Summary
Treatment standard for patients with atypical or anaplastic meningioma is neurosurgical resection. With this approach, local control ranges between 50% and 70%, depending on resection status. Carbon ions offer physical and biological characteristics Due to their inverted dose profile and the high local dose deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. 5-10% of meningiomas are of non-benign histology (atypical or anaplastic) and are associated with less favourable outcome; they are characterized by locally aggressive. After radical neurosurgical resection [4]: In patients with non-bening meningiomas treated with surgery alone, local recurrence rates are 50% for subtotally excised, and 90% for completely resected patients at 3 years as reported in a large multi-center overview. For non-benign meningiomas, a number of small and non- controlled series have reported superior outcome after postoperative radiotherapy as compared to surgery alone [6,9,10,11,12,13]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
